Oncolytic Viruses pp 1-19

Part of the Methods in Molecular Biology book series (MIMB, volume 797)

Oncolytic Herpes Simplex Virus Engineering and Preparation

Abstract

Herpes simplex virus-1 (HSV-1) is an enveloped, double-stranded DNA virus that has been used with modification as an oncolytic virus against a number of tumor types. Modifications that make HSV-1 replication-­conditional, i.e., selectively divide in replicating cells make it fulfill a prerequisite criteria for oncolytic viruses. Other appealing features of HSV-1 as an oncolytic virus include its large, modifiable genome; its sensitivity to antiviral agents, such as ganciclovir; and its lack of host cell integration. Here, we review the methods of HSV-1 engineering, through traditional recombination techniques as well as through bacterial artificial chromosome (BAC) technology. We then describe protocols for titering, amplification, and purification of engineered HSV-1-derived oncolytic viruses.

Key words

Oncolytic virus Virus titer Virus purification HSV-BAC G47Δ 

References

  1. 1.
    Chiocca, E. A. (2002). Oncolytic viruses. Nat Rev Cancer 2, 938–50.Google Scholar
  2. 2.
    Aghi, M., and Chiocca, E. A. (2003). Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review. Cancer Invest 21, 278–92.Google Scholar
  3. 3.
    Shen, Y., and Nemunaitis, J. (2006). Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 13, 975–92.Google Scholar
  4. 4.
    Aghi, M., and Martuza, R. (2005). Oncolytic viral therapies - the clinical experience. Oncogene 24, 7802–16.Google Scholar
  5. 5.
    Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854–6.Google Scholar
  6. 6.
    Markert, J. M., Parker, J. N., Buchsbaum, D. J., Grizzle, W. E., Gillespie, G. Y., and Whitley, R. J. (2006). Oncolytic HSV-1 for the treatment of brain tumours. Herpes : the journal of the IHMF 13, 66–71.Google Scholar
  7. 7.
    Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938–43.Google Scholar
  8. 8.
    Kramm, C. M., Chase, M., Herrlinger, U., Jacobs, A., Pechan, P. A., Rainov, N. G., Sena-Esteves, M., Aghi, M., Barnett, F. H., Chiocca, E. A., and Breakefield, X. O. (1997). Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 8, 2057–68.Google Scholar
  9. 9.
    Ino, Y., Saeki, Y., Fukuhara, H., and Todo, T. (2006). Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12, 643–52.Google Scholar
  10. 10.
    Fukuhara, H., Ino, Y., Kuroda, T., Martuza, R., and Todo, T. (2005). Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Research 65, 10663–8.Google Scholar
  11. 11.
    Todo, T., Martuza, R. L., Rabkin, S. D., and Johnson, P. A. (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98, 6396–401.Google Scholar
  12. 12.
    Chou, J., Kern, E. R., Whitley, R. J., and Roizman, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250, 1262–6.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Harvard Medical SchoolBostonUSA
  2. 2.Department of NeurosurgeryUniversity of California at San FranciscoSan FranciscoUSA

Personalised recommendations